Grifols to invest EUR 180 million in Egypt plasma-derivatives expansion through 2029

• Grifols launched a 2026-2029 expansion plan for its Egypt plasma-derivatives joint venture with an additional EUR 180 million investment.
• Total investment in the project rises to EUR 460 million, including EUR 280 million already deployed.
• Plan targets plasma collection capacity of up to 3 million liters by 2029 through further rollout of donation centers.
• New industrial complex in Egypt remains on track, with the first phase set for inauguration in October 2026.
• First-phase facilities include a processing plant sized for more than 1 million liters per year, a plasma logistics center, a fully automated testing lab.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grifols SA published the original content used to generate this news brief on June 12, 2026, and is solely responsible for the information contained therein.